Glucose turnover after replacement of usual therapy by insulin in insulin-naive type 2 diabetes subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages 2225-2232

  Thabit, H ^a   Kumareswaran, K ^a   Haidar, A ^c   Leelarathna, L ^a   Caldwell, K ^a   Elleri, D ^a,b   Allen, J M ^a,b   Nodale, M ^a   Wilinska, M E ^a,b   Jackson, N C ^d   Umpleby, A M ^d   Evans, M L ^a   Hovorka, R ^a,b  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TURNOVER; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84902338987     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4519     Document Type: Article

References (46)

1. Moghissi ES. Addressing hyperglycem ia from hospital admission to discharge. Curr Med Res Opin. 2010;26:589-598.
2. Dhatariya K, Levy N, Kilvert A, et al; Joint British Diabetes Societies. NHS Diabetes guideline for the periopera tive management of the adult patient with diabetes. Diabet Med. 2012;29:420-433.
3. Juneja R. Hyperglycemia management in the hospital: about glucose targets and process improvements. PostgradMed. 2008;120:38-50.
4. Draznin B, Gilden J, Golden SH, et al; Pride Investigators. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care. 2013;36:1807-1814.
5. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endo crinol Metab. 2012;97:16-38.
6. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basalbolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34:256-261.
7. Juneja R, Foster SA, Whitema n D, Fahrbach JL. The nuts and bolts of subcutaneous insulin therapy in non-critical care hospital settings. Postgrad Med. 2010;122:153-162.
8. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006;355:1903-1911.
9. Scheen AJ, Paquot N Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013 39 179-190.
10. Radziuk J, Pye S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or li mit cycle behaviour? Diabetologia. 2006;49:1619-1628.
11. Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care. 2009;32:866-872.
12. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia. 1995;38:337-343.
13. Guthrie RM. Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgrad Med. 2012;124:82-89.
14. Singhal P, Caumo A, Cobelli C, Taylor R. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism. 2005;54:79-84.
15. Basu R, Shah P, Basu A, et al. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes. 2008;57:24-31.
16. Fé ry F, Plat L, B alasse EO. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism. 1997;46:227-233.
17. Gastaldelli A, Nauck MA, Balena R. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism. 2013;62:1330-1339.
18. Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. 2013;56:156-161.
19. Kumareswaran K, T habit H, Leelarathna L, et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomised controlled study [published online September 11, 2013]. Diabetes Care. doi:10.2337/dc13-1030.
20. Haidar A, Elleri D, Allen JM, et al. Validity of triple-and dual-tracer techniques to estimate glucose appearance.AmJ Physiol Endocrinol Metab. 2012;302:E1493-E1501.
21. Haidar A, Potocka E, Boulet B, Umpleby AM, Hovorka R. Estimating postprandial glucose fluxes using hierarchical Bayes modelling. Comput Methods Programs Biomed. 2012;108:102-112.
22. Shojaee-Moradie F, Jackson NC, Jones RH, Mallet AI, Hovorka R, Umpleby AM. Quantitative measurement of 3-O-methyl-D-glucose by gas chromatography-mass spectrometry as a measure of glucose transport in vivo. J Mass Spectrom. 1996;31:961-966.
23. Hovorka R, Shojaee-Moradie F, Carroll PV, et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am J Physiol Endocrinol Metab. 2002;282:E992-E1007.
24. Hovorka R, Jayatillake H, Rogatsky E, Tomuta V, Hovorka T, Stein DT. Calculating glucose fluxes during meal tolerance test: a new computational approach. Am J Physiol Endocrinol Metab. 2007; 2 93:E610-E619.
25. Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS-A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325-337.
26. Mari A. Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol. 1992;263:E400-E415.
27. Murphy HR, Elleri D, Allen JM, et al. Pathophysiology of postprandial hyperglycaemia inwomenwith type 1 diabetes during pregnancy. Diabetologia. 2012;55:282-293.
28. Elleri D, Allen JM, Harris J, et al. Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. Diabetologia. 2013;56:1108-1117.
29. Moghissi ES, Korytkowski MT, DiNardo M, et al; American Association of Clinical Endocrinologists, American Diabetes As sociation. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-1131.
30. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12:57-69.
31. Guan Y,Hao C,Cha DR,et al Thiazolidinediones expand body fluid volume through PPAR-stimulation of ENaC-mediated renal salt absorption Nat Med. 2005 11 861-866.
32. Abdelmoneim AS, Hasenbank SE, Seubert JM, Bro cksDR,Light PE, Simpson SH. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab. 2012;14:130-138.
33. Glass LC, Cusi K, Berria R, et al. Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with type 2 diabetes: a double tracer OGTT study. Clin Endocrinol (Oxf). 2010;73:339-345.
34. He YL. Cli nical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51:147-162.
35. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-2176.
36. Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. Diabetes. 2012;61:301-30 9.
37. Kraegen EW, Lazarus L, Campbell LV. Failure of insulin infusion during euglycemia to influence endogenous basal insulin secretion. Metabolism. 1983;32:622-627.
38. Shima K, Morishta S, Sawazaki N, Tanaka R, Tarui S. Failure of exogenous insulin to inhibit insulin secretion in man. Horm Metab Res. 1977;9:441-443.
39. Argoud GM, Schade DS, Eaton RP. Insulin suppresses its own secretion in vivo. Diabetes. 1987;36:959-962.
40. Goldfine AB, Kulkarni RN. Modulation of-cell function: a translational journey from the bench to the bedside. Diabetes Obes Metab. 2012;14 Suppl 3:152-160.
41. Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab. 2014;16:1-8.
42. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia. 2005;48:420-426.
43. Solis-Herrera C, Triplitt C, Garduno-Garcia Jde J, Adams J, De-Fronzo RA, Cersosimo E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes Care. 2013;36:2756-2762.
44. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hypergly caemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
45. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patientcentered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
46. Hawkins M, Gabriely I, Wozniak R, Reddy K, Ros setti L, Shamoon H. Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes. 2002;51:2179-2189.